Mangayarkarasi V Babu

Dr. Mangayarkarasi V Babu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Advances in Medical Education and Practice
Verified
Journal Article
Open access
PDF file
MBMangayarkarasi V Babu
Mangayarkarasi V Babu
MAMohan Kumar Arumugam
Mohan Kumar Arumugam
DDDhrubajyoti J. Debnath
Dhrubajyoti J. Debnath
Background: An in-situ simulation model with a simulated patient environment is a training tool that was implemented for the front-line workers managing COVID-19 respiratory infection outbreak in a hospital of National Importance, situated in southern part of India. The objective of this training tool was to improve the preparedness of health care workers and the control measures to manage any respiratory infection outbreaks. Also, to provide good patient care and patient safety during the sudden outbreak of SARS-CoV-2, the pathogen causing pandemic respiratory infection outbreak worldwide. Methods: Simulated patient environment is a kind of functional mock drill that was applied to assess and improve the readiness of the healthcare workers of the hospital to identify the patient at the screening area, guide the patient for investigation and inform the public health system during an outbreak of an infection. The faculty of the Department of Microbiology, Community and Family Medicine, and General Medicine were the educators and demonstrators. Fifty healthcare workers from All India Institute of Medical Sciences (AIIMS), Mangalagiri, Ministry of Health and Family Welfare (MOHFW), Government of India, such as doctors, epidemiologists, nurses, laboratory technicians, laboratory attendants, members of infection control team and biomedical waste management team participated in this program. Results: Statistical analysis of the results with pre-intervention and post-intervention assessments and feedback from the participants was done at the end of the program. The difference between the mean of pre-intervention and post-intervention scores in doctors, nurses, and other health care professionals was statistically very highly significant (P-value < 0.001). Conclusion: The training method was the simulation of management of pandemic respiratory infection outbreaks in the most realistic manner possible to test or evaluate the capability of more than one function in the context of an emergency event. An in-situ simulation is an effective method that is close to real-life scenario, to measure the readiness and effectiveness of an emergency response plan. Hence, it is a useful tool to assess disaster preparedness against any type of outbreak.

31 March 2025
Verified
Journal Article
Open access
JRJyotismita Rajbongshi
Jyotismita Rajbongshi
MBMangayarkarasi V Babu
Mangayarkarasi V Babu
EDElantamilan Durairaj
Elantamilan Durairaj
This narrative review explores the critical role of antifungal stewardship (AFS) programs in optimizing antifungal use to improve patient outcomes and combat the rising threat of antifungal resistance. The global incidence of invasive fungal infections (IFIs) is increasing, necessitating urgent and effective AFS strategies. We outline the core principles of AFS, including appropriate antifungal selection, tailored treatment, optimized therapy, timely initiation and de-escalation, minimizing adverse effects, reducing healthcare costs, and preventing resistance emergence. Key components essential for the successful implementation of AFS programs are discussed. Current AFS practices are examined, highlighting significant variability in implementation across healthcare settings due to resource availability, local epidemiology, and provider expertise. Additionally, evidence on the effectiveness of AFS programs across multiple institutions worldwide is reviewed. The limitations hindering widespread AFS adoption, including resource constraints, diagnostic challenges, lack of standardization, and inadequate training, are acknowledged. Potential solutions such as enhanced collaboration, comprehensive education and training programs, and a One Health approach to address health disparities are proposed. AFS plays a central role in optimizing antifungal use, improving patient outcomes, and preserving the effectiveness of these essential therapies for future generations.


27 August 2026 in Indian Journal of Medical Microbiology
Verified
Journal Article
Closed access
VGVithiya Ganesan
Vithiya Ganesan
SPShunmuga Sundaram Ponnusamy
Shunmuga Sundaram Ponnusamy
MBMangayarkarasi V Babu
Mangayarkarasi V Babu
BYB. Yuvaraj
B. Yuvaraj

31 March 2025
Verified
Journal Article
Open access
EDElantamilan Durairaj
Elantamilan Durairaj
JRJyotismita Rajbongshi
Jyotismita Rajbongshi
MBMangayarkarasi V Babu
Mangayarkarasi V Babu

15 September 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
MBMangayarkarasi V Babu
Mangayarkarasi V Babu
DDDhrubajyoti J. Debnath
Dhrubajyoti J. Debnath
MTMukesh Tripathi
Mukesh Tripathi
SYSamata Yalamanchil
Samata Yalamanchil
SSSumita Shankar
Sumita Shankar
PKPradeep Kumar
Pradeep Kumar
Healthcare workers (HCWs) in India received the AZD1222 and BBV152 vaccines from January 2021 onwards. The objective of this study was to compare the immune response (seropositivity rate and geometric mean titer (GMT), and 95% confidence interval (CI)] against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in HCWs who received these vaccines, after the first and second doses. Therefore, the total immunoglobulin (Ig) levels specific to SARS-CoV-2 were measured using quantitative enzyme-linked immunosorbent assay (ELISA). The study population of 133 HCWs consisted of two groups in which the immune response was measured for the AZD1222 and BBV152 vaccines. Data collection was performed from 6 February to 20 August 2021. Four weeks after the first and second dose, the odds ratio of seroconversion for AZD1222 and BBV152 vaccine was 10.3 times (95% CI: 4.5–23.7) and 15.9 times (95% CI: 6.3–39.9), respectively. The GMT was 6392.93 and 6398.82 U/mL for AZD1222 and 1480.47 and 990.38 U/mL for BBV152 after the first and second doses, respectively. Both vaccines elicited an immune response, but the seroconversion rate and GMT after each dose were significantly higher for AZD1222 than those for the BBV152 vaccine in this study.